gdc
PSS Guide 2023
Cervical CancerFinancial Support

Drugs for Cervical Cancer

Find financial assistance programs available for cervical cancer drugs.

Avastin (bevacizumab) Injection

Drug company: Genentech
866-422-2377

Genentech Oncology offers 2 financial assistance programs for patients using Avastin:

Genentech Oncology Co-pay Assistance Program

Genentech Patient Foundation

Hycamtin (topotecan) Injection

Drug company: Novartis
800-282-7630

Novartis Patient Assistance NOW Oncology offers 1 financial assistance program for patients using Hycamtin:

Novartis Patient Assistance Foundation

Keytruda (pembrolizumab)

Drug company: Merck
855-257-3932

Merck offers 2 financial assistance programs for patients using Keytruda:

Merck Co-pay Assistance Program

Merck Patient Assistance Program

Mvasi (bevacizumab-awwb)

Drug company: Amgen
888-427-7478

Amgen Assist 360 offers 2 financial assistance programs for patients who have been prescribed Mvasi:

Amgen FIRST STEP Co-Pay Program

Amgen Safety Net Foundation

Tivdak (tisotumab vedotin-tftv) Injection

Drug company: Seagen
855-473-2873

Seagen Secure offers 2 financial assistance programs for patients using Tivdak:

Commercial Out-Of-Pocket Assistance Program

Patient Assistance Program

Zirabev (bevacizumab-bvzr) Injection

Drug company: Pfizer
877-744-5675

Pfizer Oncology Together offers 2 financial assistance programs for patients who have been prescribed Zirabev:

Pfizer Oncology Together Co-Pay Savings Program

Pfizer Patient Assistance Program

Table. Drugs Prescribed for Cervical Cancer

  • Drug name (generic name)
  • Drug company
  • Indications
  • Patient support services

    Drug name (generic name)
  • Hycamtin (topotecan) Injection
  • Drug company
  • Novartis
  • Indication
  • Treatment of stage IVB, recurrent or persistent carcinoma of the cervix, in combination with cisplatin
  • Patient support services
  • Novartis Patient Assistance Foundation
    800-277-2254

    Drug name (generic name)
  • Keytruda (pembrolizumab)
  • Drug company
  • Merck
  • Indication
  • Treatment of recurrent or metastatic cervical cancer progressing during or after chemotherapy in patients whose tumors express PD-L1, as determined by an FDA-approved test

    Treatment, in combination with chemotherapy and with or without Avastin, in patients with persistent, recurrent, or metastatic cervical cancer whose tumor expresses PD-L1, as determined by an FDA-approved test
  • Patient support services
  • Merck Co-pay Assistance Program
    855-257-3932

    Merck Patient Assistance Program
    855-257-3932

    Drug name (generic name)
  • Mvasi (bevacizumab-awwb)
  • Drug company
  • Amgen
  • Indication
  • Treatment of persistent, recurrent, or metastatic cervical cancer, in combination with chemotherapy
  • Patient support services
  • Amgen FIRST STEP Co-Pay Program
    866-264-2778

    Amgen Safety Net Foundation
    866-264-2778


Last modified: March 9, 2023

Report Broken Links

Have you encountered a problem with a URL (link) on this page not working or displaying an error message?

Help us fix it! Report broken links here.

Report Broken Link

Subscribe to Conquer: the journey informed

Receive timely cancer news & updates, patient stories, and more.


Country
Race or Ethnicity
Gender
Profession or Role
Primary Interest
Other Interests